feed,title,long_url,short_url
Benzinga,"Horizon Therapeutics Does Not Have Meaningful Upside, Analyst Initiating Coverage Says",https://benzinga.com/general/biotech/22/11/29506484/horizon-therapeutics-does-not-have-meaningful-upside-analyst-initiating-coverage-says,https://bit.ly/3h3BgYL
Benzinga,"Thomson Reuters Clocks 3% Revenue Growth In Q3; Reaffirms FY22, FY23 Outlook",https://benzinga.com/news/earnings/22/11/29504333/thomson-reuters-clocks-3-revenue-growth-in-q3-reaffirms-fy22-fy23-outlook,https://bit.ly/3FykjQw
